Preferred Cell Systems
Preferred Cell Systems manufactures proprietary in vitro assay kits, reagents, and culture media for lympho-hematopoietic stem and progenitor cell research, cellular therapy QC, and standardized toxicity testing, selling directly via e-commerce and international distributors to biopharmaceutical companies, academic researchers, and cellular therapy developers.
- Company typePrivate
- Founded2017
- HeadquartersColorado Springs, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Preferred Cell Systems does
Preferred Cell Systems™ is a privately held life sciences company headquartered in Colorado Springs, Colorado, that manufactures and sells proprietary in vitro assay kits, reagents, and culture media for stem cell research, cellular therapy, and toxicity testing. The company is the exclusive manufacturer and supplier of the assay and reagent portfolio originally developed by HemoGenix, with HemoGenix retaining contract research services on an adjacent basis. Its product architecture centers on the proprietary Suspension Expansion Culture™ (SEC™) technology, which replaces traditional methylcellulose-based colony-forming assays with suspension culture formats compatible with standard pipettes, and on three core detection chemistries: ATP bioluminescence (HALO®, HemoGLO™), resazurin/resorufin fluorescence (HemoFLUOR™, MultiCellGro™, ImmunoFluor™ family), and WST-1 tetrazolium absorbance (HemoLIGHT™).
The portfolio spans lympho-hematopoietic cell viability and proliferation assays, a standardized hematotoxicity platform (HALO®-Tox HT) reportedly used by half of the top 50 biopharmaceutical companies, dedicated toxicity assays for stem cell lines (STEMGlo-Tox HT) and immunotoxicity (ImmunoGlo-Tox HT), a 1-day cellular therapy quality assay (Keystone Assay™), and an organ-specific toxicology suite covering cardiotoxicity, hepatotoxicity, neurotoxicity, nephrotoxicity, dermal toxicity, intestinal toxicity, tumor cell toxicity, and mesenchymal toxicity. Supported species include human, mouse, rat, dog, horse, pig, sheep, and non-human primate.
The business is a B2B reagent and kit manufacturer operating a product-led growth motion: customers discover products through the company website, assisted search tools, instructional videos, and a direct e-commerce storefront, with international distribution via a published distributor network. Revenue is generated from one-time per-kit purchases priced from approximately $687 to over $6,000 per kit depending on assay complexity, species, cell population, and plate count. Customer segments span biopharmaceutical drug-development teams, academic and life sciences researchers, cellular therapy developers, and veterinary researchers, with no disclosed revenue, headcount, funding, or ownership data.
Preferred Cell Systems firmographics
Firmographics- Name
- Preferred Cell Systems
- Legal name
- Preferred Cell Systems
- Website
- https://preferred-cell-systems.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Preferred Cell Systems manufactures proprietary in vitro assay kits, reagents, and culture media for lympho-hematopoietic stem and progenitor cell research, cellular therapy QC, and standardized toxicity testing, selling directly via e-commerce and international distributors to biopharmaceutical companies, academic researchers, and cellular therapy developers.
- Ownership category
- akta.pro rank
Preferred Cell Systems industry classification
Industry- Product category
- Stem Cell Assay Kits and Reagents
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
- akta.pro secondary industries
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where Preferred Cell Systems is headquartered
LocationHeadquarters
- HQ city
- Colorado Springs
- HQ country
- United States
- HQ region
- North America
Markets served
Preferred Cell Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Assay Kits and Reagents: The company generates revenue from the sale of standardized in vitro assay kits and reagents. Products include HALO®, HemoGLO™, HemoFLUOR™, HemoLIGHT™, HemaToxFlow™, STEMGlo™-Tox HT, MultiCellGro™, and related reagent kits. Kits are sold with catalog numbers specifying cell type, species, formulation (low serum or serum-free), and plate count. Pricing is per kit (e.g., STEMGlo-Tox HT at $1,980.15, HemaToxFlow at ~$856-$972 depending on formulation).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Single-assay kit pricing per catalog number |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Preferred Cell Systems product offering
Product offeringCore offering
Preferred Cell Systems manufactures and sells standardized in vitro assay kits, reagents, and culture media built on proprietary Suspension Expansion Culture™ (SEC™) technology for measuring cell viability, proliferation, and cytotoxicity in lympho-hematopoietic stem and progenitor cells. Its portfolio spans ATP bioluminescence (HALO®, HemoGLO™), fluorescence (HemoFLUOR™), and absorbance (HemoLIGHT™) assay platforms, plus multi-lineage (MultiCellGro™), flow cytometry (HemaToxFlow™), and high-throughput toxicity (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT) assays serving biopharma, academic, cellular therapy, and veterinary researchers across 8 species.
Product overview
Preferred Cell Systems™ is a life sciences company that manufactures culture media, reagents, and in vitro assays for stem cell research, cellular therapy, and toxicity testing. The company's product portfolio centers on its proprietary Suspension Expansion Culture™ (SEC™) Technology platform, which replaces traditional methylcellulose-based colony-forming assays with faster, more objective, instrument-based assays. The core product line includes four main assay platforms: HALO® (standardized/validated ATP bioluminescence), HemoGLO™ (simplified ATP bioluminescence), HemoFLUOR™ (fluorescence), and HemoLIGHT™ (absorbance) — all for measuring lympho-hematopoietic cell viability and proliferation. Additional products include MultiCellGro™ for multi-lineage analysis, HemaToxFlow™ for flow cytometric analysis, and a comprehensive toxicity testing suite (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT). The company also offers the CentroLIA*pc* LB962 luminescence plate reader as an instrument accessory, along with cell expansion reagents and specialized media. Products support multiple species (human, mouse, primate, rat, dog, horse, pig, sheep) and various cell types including stem cells, progenitor cells, and immune cells.
Differentiator
Problem solved
Functional benefit
Brands
- HALO®: Standardized and validated bioluminescence research assay platform for lympho-hematopoietic cells
- HemoGLO™
- HemoFLUOR™
- HemoLIGHT™
- MultiCellGro™
- HemaToxFlow™
- HALO-Tox HT
- ImmunoGlo™
- ImmunoFluor™
- LIVEGlo™
- STEMGlo™-Tox HT
- MultiCellGro™
Products and services
- HALO® (Hematopoietic Assays via Luminescence Output)
Quantifiable outcome
- HALO®-Tox HT is used by half of the top 50 biopharmaceutical companies worldwide
- +2 more outcomes
Companies that use Preferred Cell Systems
Customer profileSegments4 records
Ideal customer profiles4 records
Preferred Cell Systems technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature11 records
Preferred Cell Systems partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- HemoGenixcorePreferred Cell Systems is the exclusive manufacturer and supplier of all reagents and in vitro assays originally produced by HemoGenix. HemoGenix continues to provide contract research services. Both companies share phone numbers ((719) 264-6251 for Preferred Cell Systems, (719) 264-6250 for HemoGenix) and appear to have an operational relationship where HemoGenix originated the product line and PCS now manufactures and distributes the products.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Preferred Cell Systems competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Charles River provides preclinical safety and toxicology services plus specialty research models (including stem cell and hematotoxicity assays). Comparable to PCS in the in vitro toxicology space, but as a much larger CRO rather than a pure reagent manufacturer.
- Promega Corporation: Promega is a major life sciences tools company offering ATP bioluminescence assays (CellTiter-Glo®) for cell viability. Comparable to PCS because it serves the same research market with similar core technology (ATP-based viability/toxicity readouts), but operates at vastly larger scale with broader product portfolio.
- Bio-Techne (R&D Systems): Bio-Techne offers cell biology reagents, stem cell research tools, and assay kits through brands like R&D Systems and Tocris. Comparable to PCS as a broader life sciences reagent supplier with overlapping cell viability and proliferation product lines, though Bio-Techne is a much larger, diversified public company.
- Lonza Bioscience: Lonza Bioscience provides cell and gene therapy manufacturing tools, including potency and viability assays, alongside broader bioprocessing offerings. Comparable to PCS in cellular therapy QC and primary cell culture reagents, though Lonza operates at significantly larger scale across pharma services.
- PerkinElmer (Revvity): PerkinElmer (now Revvity) provides cell-based assay platforms, luminescence readers, and life sciences reagents for toxicity and cell viability testing. Comparable to PCS in offering both instruments and assay kits for cell-based readouts, though at a much larger scale.
- Thermo Fisher Scientific (Life Sciences Solutions): Thermo Fisher's Life Sciences division offers a broad portfolio of cell-based assays, viability reagents, and stem cell research tools. Comparable to PCS as an incumbent with overlapping cell biology and toxicology product lines, though much larger and more diversified.
Regional players
- HemoGenix: HemoGenix is the company that originally developed the reagents and assays now exclusively manufactured by PCS; it currently focuses on contract research services (CRO). Highly comparable as the origin of PCS's product line and the implicit R&D partner, though HemoGenix operates as a service provider rather than a product manufacturer.
Emerging players
- Cisbio (Revvity): Cisbio (part of Revvity) provides HTRF® cell-based assays for GPCR and kinase research, including viability and cytotoxicity readouts. Comparable to PCS as a specialized cell-based assay developer in the research/biopharma market.
Direct peers
- STEMCELL Technologies: STEMCELL Technologies is a leading developer of specialty reagents and assays for hematopoietic stem cell research, including colony-forming cell (CFC) assays that PCS's HALO® platform directly replaces. Highly comparable in target customer (stem cell and cellular therapy researchers) and product category (specialized stem cell assays).
- CellGenix: CellGenix specializes in cell and gene therapy raw materials, including cytokines and cell culture reagents for hematopoietic cell therapy manufacturing. Comparable to PCS in serving the cellular therapy and regenerative medicine market with overlapping hematopoietic and immune cell reagents.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Preferred Cell Systems social profiles
Digital presencePreferred Cell Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Preferred Cell Systems leadership team
Management profileNumber of profiles
Preferred Cell Systems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Preferred Cell Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Preferred Cell Systems
What does Preferred Cell Systems do?
Preferred Cell Systems manufactures and sells standardized in vitro assay kits, reagents, and culture media built on proprietary Suspension Expansion Culture™ (SEC™) technology for measuring cell viability, proliferation, and cytotoxicity in lympho-hematopoietic stem and progenitor cells. Its portfolio spans ATP bioluminescence (HALO®, HemoGLO™), fluorescence (HemoFLUOR™), and absorbance (HemoLIGHT™) assay platforms, plus multi-lineage (MultiCellGro™), flow cytometry (HemaToxFlow™), and high-throughput toxicity (HALO-Tox HT, STEMGlo-Tox HT, ImmunoGlo-Tox HT) assays serving biopharma, academic, cellular therapy, and veterinary researchers across 8 species.
Is Preferred Cell Systems a public or private company?
Preferred Cell Systems is a private company. It is classified as unknown and is currently operating.
When was Preferred Cell Systems founded?
Preferred Cell Systems was founded in 2017. It employs 1 to 10 people.
Where is Preferred Cell Systems based?
Preferred Cell Systems is headquartered in Colorado Springs, United States, in the North America region.
How does Preferred Cell Systems make money?
One revenue line is on record: assay Kits and Reagents.
Who are Preferred Cell Systems's main competitors?
Broad incumbents on record are Charles River Laboratories, Promega Corporation, Bio-Techne (R&D Systems), Lonza Bioscience, PerkinElmer (Revvity) and Thermo Fisher Scientific (Life Sciences Solutions). HemoGenix is listed as a regional player. Cisbio (Revvity) is listed as an emerging player. Direct peers are STEMCELL Technologies and CellGenix.
Does Preferred Cell Systems have an API?
No public API is recorded for Preferred Cell Systems.
What industry is Preferred Cell Systems in?
Preferred Cell Systems's product category is Stem Cell Assay Kits and Reagents. Its primary akta.pro industry code is HLAGADAH, Cell-Based & Potency Assays (Bioassays), with a secondary code of HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip). Its NAICS code is 325413 and its SIC code is 2835.